The online version of this article (https://doi.org/10.1007/s10461-018-2335-7) contains supplementary material, which is available to authorized users.
To achieve UNAIDS 90:90:90 targets at population-level, knowledge of HIV status must be followed by timely linkage to care, initiation and maintenance of antiretroviral therapy (ART) for all people living with HIV (PLHIV). Interpreting quantitative patterns using qualitative data, we investigate time taken to link to care and initiate ART amongst individuals aware of their HIV-status in high HIV-prevalence urban communities in the HPTN 071 (PopART) study, a community-randomised trial of a combination HIV prevention package, including universal testing and treatment, in 21 communities in Zambia and South Africa. Data are drawn from the seven intervention communities where immediate ART irrespective if CD4 count was offered from the trial-start in 2014. Median time from HIV-diagnosis to ART initiation reduced after 2 years of delivering the intervention from 10 to 6 months in both countries but varied by gender and community of residence. Social and health system realities impact decisions made by PLHIV about ART initiation.
Supplementary material 1 (DOCX 23 kb)10461_2018_2335_MOESM1_ESM.docx
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;2015(373):795–807. CrossRef
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–9. CrossRef
Murnane PM, Celum C, Nelly M, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high risk heterosexuals: subgroup analyses from the Partners PrEP Study. AIDS. 2013;27(13):2155–60. CrossRef
UNAIDS 90-90-90. An ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nationals Programme on HIV/AIDS (UNAIDS); 2014.
TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–22. CrossRef
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2016. Report No.: 9241549688.
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9. CrossRef
Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;7(2):99–105. CrossRef
Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32(1):17–23. CrossRef
World Health Organization. Consolidated guidelines on the use of anti-retrovirals for treating and preventing hiv infection: recommendations for a public health approach. Geneva: WHO; 2013.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57. CrossRef
Iwuji CC, Orne-Gliemann J, Larmarange J, Okesola N, Tanser F, Thiebaut R, et al. Uptake of home-based HIV testing, linkage to care, and community attitudes about ART in rural KwaZulu-Natal, South Africa: descriptive results from the first phase of the ANRS 12249 TasP cluster-randomised trial. PLoS Med. 2016;13(8):e1002107. CrossRef
Katz IT, Maughan-Brown B. Improved life expectancy of people living with HIV: who is left behind? Lancet HIV. 2017;4(8):e324–6. CrossRef
Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13(5):e1002015. CrossRef
Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2017; in press.
Grabowski M, Serwadda D, Gray R, Nakigozi G, Kigozi G, Kagaayi J, et al. HIV prevention efforts and incidence of HIV in Uganda. N Engl J Med. 2017;377(22):2154–66. CrossRef
Official Press Releases ‘New HIV data from sub-Saharan Africa highlight challenges and reasons for hope’ 22nd International AIDS Conference, Amsterdam, the Netherlands, 23–27 July 2018: http://www.aids2018.org/Media-Centre/The-latest/Press-releases/ArticleID/188/New-HIV-data-from-sub-Saharan-Africa-highlight-challenges-and-reasons-for-hope; 2018.
Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment—a study protocol for a cluster randomised trial. Trials. 2014;15(1):57. CrossRef
Curran K, Ngure K, Shell-Duncan B, Vusha S, Mugo NR, Heffron R, et al. If I am given antiretrovirals I will think I am nearing the grave’: Kenyan HIV serodiscordant couples’ attitudes regarding early initiation of antiretroviral therapy. AIDS. 2014;28(2):227–33. CrossRef
Katz IT, Dietrich J, Tshabalala G, Essien T, Rough K, Wright AA, et al. Understanding treatment refusal among adults presenting for HIV-testing in Soweto, South Africa: a qualitative study. AIDS Behav. 2015;19(4):704–14. CrossRef
Kiwanuka J, Kiwanuka N, Kiweewa F, Perez JG, Kitonsa J, Mukulu JW. Factors associated with loss to follow-up in a primary healthcare HIV clinic practising test and treat (conference abstract). J Int AIDS Soc. 2017;20:19.
Mbonye M, Seeley J, Nalugya R, Kiwanuka T, Bagiire D, Mugyenyi M, et al. Test and treat: the early experiences in a clinic serving women at high risk of HIV infection in Kampala. AIDS Care. 2016;28(sup3):33–8. CrossRef
Mocroft A, Lundgren JD, Sabin ML, Monforte AA, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013;10(9):e1001510. CrossRef
Parrott FR, Mwafulirwa C, Ngwira B, Nkhwazi S, Floyd S, Houben RM, et al. Combining qualitative and quantitative evidence to determine factors leading to late presentation for antiretroviral therapy in Malawi. PLoS ONE. 2011;6(11):e27917. CrossRef
Renju J, Moshabela M, McLean E, Ddaaki W, Skovdal M, Odongo F, et al. ‘Side effects’ are ‘central effects’ that challenge retention in HIV treatment programmes in six sub-Saharan African countries: a multicountry qualitative study. Sex Transm Infect. 2017;93(Suppl 3):e052971. CrossRef
Plazy M, El Farouki K, Iwuji C, Okesola N, Orne-Gliemann J, Larmarange J, et al. Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South Africa. J Int AIDS Soc. 2016;19(1):20913. CrossRef
De Cock KM. Editorial commentary: Plus ça change… Antiretroviral therapy, HIV prevention, and the HIV treatment cascade. Clin Infect Dis. 2014;58(7):1012–4. CrossRef
Evans C, Bennett J, Croston M, Brito-Ault N, Bruton J. “In reality, it is complex and difficult”: UK nurses’ perspectives on “treatment as prevention” within HIV care. AIDS Care. 2015;27(6):753–7. CrossRef
Karim QA, Dellar RC, Bearnot B, Werner L, Frohlich JA, Kharsany AB, et al. HIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventions. AIDS Behav. 2015;19(2):322–9. CrossRef
Sugarman J. Bioethical challenges with HIV treatment as prevention. Clin Infect Dis. 2014;59(Suppl 1):S32–4. CrossRef
Wilson D, Fraser N. Who pays and why? Costs, effectiveness, and feasibility of HIV treatment as prevention. Clin Infect Dis. 2014;59(Suppl 1):S28–31. CrossRef
Kawuma R, Seeley J, Mupambireyi Z, Cowan F, Bernays S, on behalf of the REALITY Trial Team. ‘Treatment is not yet necessary’: delays in seeking access to HIV-treatment in Uganda and Zimbabwe. Afr J AIDS Res. 2018; in press.
Hargreaves J, Krishnaratne S, Mathema H, Lilleston P, Sievwright K, Mandla N, et al. Individual and community-level risk factors for HIV stigma in 21 Zambian and South African communities: analysis of data from the HPTN 071 (PopART) study. AIDS. 2018;32(6):783–93. CrossRef
Shanaube K, Schaap A, Floyd S, Phiri M, Griffith S, Chaila J, et al. What works–reaching universal HIV testing: lessons from HPTN 071 (PopART) trial in Zambia. AIDS. 2017;31(11):1555–64. CrossRef
Hayes R, Floyd S, Schaap A, Shanaube K, Bock P, Sabapathy K, et al. A universal testing and treatment intervention to improve HIV control: one-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. PLoS Med. 2017;14(5):e1002292. CrossRef
Bond V, Hoddinott G, Viljoen L, Simuyaba M, Musheke M, Seeley J, et al. Good health and moral responsibility: key concepts underlying the interpretation of treatment as prevention in South Africa and Zambia before rolling out universal HIV testing and treatment. AIDS Patient Care STDs. 2016;30(9):425–34. CrossRef
Hargreaves JR, Stangl A, Bond V, Hoddinott G, Krishnaratne S, Mathema H, et al. HIV-related stigma and universal testing and treatment for HIV prevention and care: design of an implementation science evaluation nested in the HPTN 071 (PopART) cluster-randomized trial in Zambia and South Africa. Health Policy Plan. 2016;31(10):1342–54. CrossRef
Bond V, Nomsenge S, Mwamba M, Ziba D, Birch A., Mubekapi-Musadaidzwa C, et al. “Being seen” at the clinic: Zambian and South African health worker reflections on the relationship between health facility spatial organisation and items and HIV stigma in 21 health facilities, the HPTN 071 (PopART) study. Health Place; 2019 (in press).
Bock P, Phiri C, Piwowar-Manning E, Kosloff B, Mandla N, Young A, et al. Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa. J Int AIDS Soc. 2017;20(S6):21780. CrossRef
Simwinga M, Bond V, Makola N, Hoddinott G, Belemu S, White R, et al. Implementing community engagement for combination prevention: lessons learnt from the first year of the HPTN 071 (PopART) community-randomized study. Curr HIV/AIDS Rep. 2016;13(4):194–201. CrossRef
Bond V, Chiti B, Hoddinott G, Reynolds L, Schaap A, Simuyaba M, et al. “The difference that makes a difference”: highlighting the role of variable contexts within an HIV Prevention Community Randomised Trial (HPTN 071/PopART) in 21 study communities in Zambia and South Africa. AIDS Care. 2016;28(sup3):99–107. CrossRef
Bond V, Ngwenya F, Murray E, Ngwenya N, Viljoen L, Gumede D, et al. Value and limitations of broad brush surveys used in community-randomized trials in Southern Africa. Qual Health Res. 2019; in press.
Bond V, Ngwenya F, Thomas A, Simuyaba M, Hoddinott G, Fidler S, et al. Spinning plates: livelihood mobility, household responsibility and anti-retroviral treatment in an urban Zambian community during the HPTN 071 (PopART) study. J Int AIDS Soc. 2018;21(4):e25117. CrossRef
Nattrass N. Gender and access to antiretroviral treatment in South Africa. Fem Econ. 2008;14(4):19–36. CrossRef
Treves-Kagan S, Steward WT, Ntswane L, Haller R, Gilvydis JM, Gulati H, et al. Why increasing availability of ART is not enough: a rapid, community-based study on how HIV-related stigma impacts engagement to care in rural South Africa. BMC Public Health. 2015;16(1):87. CrossRef
Koenig SP, Dorvil N, Dévieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLoS Med. 2017;14(7):e1002357. CrossRef
South Africa National Department of Health and PEPFAR. Meeting summary report: best practices and innovations in linkage to care, HIV treatment and viral suppression 31 May–01 June 2016, Pretoria, South Africa. Pretoria: South Africa National Department of Health and PEPFAR; 2016. Contract No.: https://za.usembassy.gov/wp-content/uploads/sites/19/2016/09/Meeting-Summary-Report_Best-Practices-and-Innovations-in-Linkage-Treatm.pdf.
Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE Randomized Clinical Trial. JAMA. 2018;319(11):1103–12. CrossRef
Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2012;9(12):e1001351. CrossRef
Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, et al. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016;3(3):e111–9. CrossRef
Maheswaran H, Petrou S, MacPherson P, Choko AT, Kumwenda F, Lalloo DG, et al. Cost and quality of life analysis of HIV self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. BMC Med. 2016;14(1):34. CrossRef
Zanolini A, Chipungu J, Vinikoor MJ, Bosomprah S, Mafwenko M, Holmes CB, et al. HIV self-testing in Lusaka Province, Zambia: acceptability, comprehension of testing instructions, and individual preferences for self-test kit distribution in a population-based sample of adolescents and adults. AIDS Res Hum Retrovir. 2017; in press.
PEPFAR. PEPFAR Country/Regional Operational Plan (COP/ROP) Guidance 2017. Washington, DC: U.S. Department of State; 2017.
Sabapathy K, Mubekapi-Musadaidzwa C, Mulubwa C, Schaap A, Hoddinott G, Stangl A, et al. Predictors of timely linkage-to-ART within universal test and treat in the HPTN 071 (PopART) trial in Zambia and South Africa: findings from a nested case–control study. J Int AIDS Soc. 2017. https://doi.org/10.1002/jia2.25037. CrossRefPubMedPubMedCentral
UNAIDS. Blind Spot. Reaching out to men and boys. Addressing a blind spot in the response to HIV. Geneva: Joint United Nationals Programme on HIV/AIDS (UNAIDS); 2017.
Mayanja Y, Kamacooko O, Bagiire D, Namale G, Kaleebu P, Seeley J. ‘Test and treat’ among women at high risk for HIV-infection in Kampala, Uganda: antiretroviral therapy initiation and associated factors. AIDS Behav. 2017;22(3):1053–61. CrossRef
Prust ML, Banda CK, Nyirenda R, Chimbwandira F, Kalua T, Jahn A, et al. Multi-month prescriptions, fast-track refills, and community ART groups: results from a process evaluation in Malawi on using differentiated models of care to achieve national HIV treatment goals. J Int AIDS Soc. 2017;20(S4):21650. CrossRef
Wilkinson L, Harley B, Sharp J, Solomon S, Jacobs S, Cragg C, et al. Expansion of the Adherence Club model for stable antiretroviral therapy patients in the Cape Metro, South Africa 2011–2015. Trop Med Int Health. 2016;21(6):743–9. CrossRef
McNairy ML, El-Sadr WM. The HIV care continuum: no partial credit given. AIDS. 2012;26(14):1735–8. CrossRef
MacCarthy S, Hoffmann M, Ferguson L, Nunn A, Irvin R, Bangsberg D, et al. The HIV care cascade: models, measures and moving forward. J Int AIDS Soc. 2015;18(1):19395. CrossRef
Fox MP, Rosen S. A new cascade of HIV care for the era of “treat all”. PLoS Med. 2017;14(4):e1002268. CrossRef
Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8(7):e1001056. CrossRef
Forhan SE, Modi S, Houston JC, Broyles LN. Moving toward test and start: learning from the experience of universal antiretroviral therapy programs for HIV-infected pregnant/breastfeeding women. AIDS. 2017;31(10):1489–93. CrossRef
Chan AK, Kanike E, Bedell R, Mayuni I, Manyera R, Mlotha W, et al. Same day HIV diagnosis and antiretroviral therapy initiation affects retention in Option B + prevention of mother-to-child transmission services at antenatal care in Zomba District, Malawi. J Int AIDS Soc. 2016;19(1):20672. CrossRef
Geffen N, Robinson M, Venter F, Low M. One size doesn’t fit all: tailoring adult antiretroviral treatment. S Afr J HIV Med. 2014;15(3):77–8. CrossRef
Grimsrud A, Bygrave H, Doherty M, Ehrenkranz P, Ellman T, Ferris R, et al. Reimagining HIV service delivery: the role of differentiated care from prevention to suppression. J Int AIDS Soc. 2016;19(1):21484. CrossRef
Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, et al. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature. 2015;528(7580):S68–76. CrossRef
Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. Trop Med Int Health. 2015;20(4):430–47. CrossRef
- Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa
Laing de Villiers
the HPTN 071 (PopART) study team
- Springer US
AIDS and Behavior
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254